The J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation) study demonstrated the benefit of rhythm-control compared with rate-control in Japanese patients with paroxysmal atrial fibrillation (AF), according to AF-specific quality of life scores. However, detailed information on prescribed antiarrhythmic agents remains unclear.
trial fibrillation (AF) is the most common sustained cardiac arrhythmia, and is associated with increased mortality and morbidity. [1] [2] [3] [4] Large clinical trials, such as the PIAF (Pharmacological Intervention in Atrial Fibrillation), 5 AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management), 6 RACE (Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation) 7 and STAF (Strategies of Treatment of Atrial Fibrillation) 8 trials, have been conducted to investigate whether rate control or rhythm control improves the outcome of AF, but none of them demonstrated the superiority in the long term of the rhythm control group compared with the rate control group. [5] [6] [7] [8] [9] Recently, the J-RHYTHM (Japanese Rhythm Management Trial for Atrial Fibrillation), the first randomized comparison ever conducted in Japan, demonstrated that compared with the rate-control strategy the rhythm-control strategy was associated with fewer primary endpoints when it included patients' tolerability. 10 Moreover, the AF specific quality of life score was significantly higher in the rhythm-control group. Notably, the study population in the J-RHYTHM study comprised relatively young and predominantly symptomatic patients with PAF rather than persistent AF, when compared with the previous clinical trials.
However, detailed information about each antiarrhythmic agent (AA) has not been provided. In the J-RHYTHM study, A AAs were selected by the attending physicians principally based on recommendations from the Japanese Circulation Society (JCS) Guideline for Atrial Fibrillation Management to safely and effectively maintain sinus rhythm in assigned patients. [10] [11] [12] This substudy was conducted to examine detailed information about each of the AAs used in the J-RHYTHM study.
Methods

Database of the J-RHYTHM Study
The J-RHYTHM study was a randomized multicenter comparative study of patients with PAF treated by either rate or rhythm control. 10, 12 PAF was defined as AF expected to convert spontaneously to sinus rhythm within 48 h of onset. Patients were randomly assigned to either control strategy group and the 419 patients assigned to the rhythm-control group were analyzed in this substudy. The AAs were selected by the attending physicians according to the "JCS Guideline for Atrial Fibrillation Management". 11 In this guideline, a class I drug was the drug of choice for PAF, whereas the ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation recommend flecainide, propafenone, or sotalol as the initial drug for recurrent PAF without heart disease. 13 Oral antithrombotic therapy was applied in the rhythmcontrol arm according to the protocol modified from the AFFIRM study. 6, 14 Briefly, in patients with 1 or more risk factors for stroke, warfarin was prescribed to maintain the prothrombin time-international normalized ratio (PT-INR) between 1.6 and 3.0. Anticoagulant therapy was continued throughout the study, even if sinus rhythm appeared to be maintained by the AAs. 10, 12 A total of 38 patients dropped out (6.9%) during the study, we excluded 8 patients with no medication on entry to the study (6 of them were given no drugs during the follow-up period) and 1 patient was being treated by 2-drug combinations on entry to the study.
Classification of Antiarrhythmic Agents
We classified the AAs according to the Vaughan Williams system to compare the incidence of various endpoints in the rhythm-control group of the J-RHYTHM study ( Table 1) .
Endpoints
We defined the primary endpoint as a combination of hard and soft endpoints. The hard endpoint was a composite of total mortality, symptomatic cerebral infarction, systemic embolism, major bleeding and hospitalization for heart failure requiring intravenous administration of diuretics. The soft endpoint was physical/psychological disability requiring alteration of the assigned treatment strategy.
The secondary endpoint was recurrence of AF during the follow-up period. The maintenance of sinus rhythm was confirmed by snapshot ECG recorded at the outpatient clinic every 3 months.
Statistical Analysis
Baseline clinical characteristics of patients were compared with chi-square tests and 1-way ANOVA. Rates for all timeto-event analyses were estimated by the Kaplan-Meier method 15 and were compared by the log-rank test. Secondary analyses were conducted to evaluate results within subgroups according to prescribed AAs. Unadjusted hazard ratios for the secondary endpoint were estimated by logistic regression analysis. Known clinical predictors, such as age, sex, presence or absence of congestive heart failure, coronary artery disease, valvular heart disease, cardiomyopathy, history of previous medication for AF and Vaughan Williams classification (class I vs class III), were used to construct a multivariable Cox-proportional hazard model by a stepwise procedure. A 2-tailed P value <0.05 was considered statistically significant.
Results
Baseline Patient Characteristics
For the 419 patients with PAF assigned to rhythm control, the median follow-up period was 1.7 years (interquartile 
Treatment
AAs prescribed at the beginning of study are outlined in Figure 1 . The AAs used in the rhythm-control group were different from those used in previous clinical trials. [5] [6] [7] [8] Approximately 80% of patients were started on class Ia or Ic drugs in accordance with the "The JCS Guideline for Atrial Fibrillation Management". 11 In addition, bepridil was the class III drug used in 7.3% of cases, and amiodarone was prescribed in only 0.5% of the patients as an initial therapy. Anticoagulation with warfarin was performed in 60% of the patients appropriately, according to CHADS2 risk assessment. 10
Primary Endpoint
The primary endpoint occurred in 20 (16.9), 2 (6.7), 32 (15.8) and 7 (23.3) patients (%) assigned to class Ia, Ib, Ic or III drugs, respectively. Details of events defined as the primary endpoint are outlined in Table 3 . The total mortality was 4 (1%) and did not differ significantly among the AA groups. Kaplan-Meier estimates of the first occurrence of the primary endpoint over time are shown in Figure 2A . The occurrence of the primary endpoint was not significantly different among the drug groups. A similar trend was seen AIZAWA Y et al. 
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when hard and soft endpoints were analyzed separately (Figures 2B,C) .
Secondary Endpoint
Sinus Rhythm Maintenance AF documented by snapshot ECG during follow-up occurred in 20.3, 23.3, 29.1, 50.0% of the patients assigned to class Ia, Ib, Ic or III drugs, respectively. Kaplan-Meier estimates of the first occurrence of the secondary endpoint over time are shown in Figure 2D . The recurrence of AF was significantly higher in patients treated with class III drugs (P=0.002).
Hazard Ratios in Subgroups We created a multivariable Cox proportional hazard model by stepwise procedure to exclude confounding factors. After adjustment for other clinical variables, the choice of AA was no longer associated with recurrence of AF (class I vs III, P=0.15). Hazard ratios for the secondary endpoint in the subgroups are shown in Table 4 . Presence of cardiomyopathy and history of previous rhythm control therapy were associated with the occurrence of the secondary endpoint, but the difference between class I and class III drugs was not associated with the difference in AF-free survival rate. Additionally, this trend did not alter when we excluded 6 patients with cardiomyopathy.
Discussion
Main Results
The incidence of the primary endpoint did not differ significantly between each group of AAs classified by the Vaughan Williams classification. The rhythm maintenance rate seemed to be lower with class III agents, but this effect was not independent after adjustment for other comorbidities of the patients.
The patients in the J-RHYTHM study were characterized by PAF, young age, less structural heart disease, and less previous history of congestive heart failure, predicting good prognosis. Only ~20% of patients were at high risk for stroke. Thus, the total mortality and cardiovascular morbidity rates were low compared with previous studies, in which most or all of the patients had persistent AF and were treated by amiodarone. [5] [6] [7] [8] The AAs used in the present rhythmcontrol group were also different from those used in previous studies, [5] [6] [7] [8] 10, 12 in which physicians selected the drugs principally according to the "The Japanese Guideline for Atrial Fibrillation Management". 11 In the present study, a total of 30.2% patients were started on class Ia drugs, 7.7% on Ib drugs, 52.0% on Ic drugs, and 7.7% on III drugs (7.3% of bepridil and 0.5% of amiodarone). Bepridil, a multichannel blocker, is a reverse remodeling agent that has had its efficacy established by several studies conducted in Japan. [16] [17] [18] [19] [20] [21] The present study shows that in the rhythm-control group, the hard and soft endpoints were not affected by the selection of AA. Regarding the long-term safety of class III agents, there was 1 death during the follow-up period. Because our analysis did not have a control group for reference, we were unable to draw a definite conclusion about the use of bepridil. The recently published J-BAF study also demonstrated drug-related adverse effects that suggest caution about using bepridil. 20 The maintenance of sinus rhythm was significantly decreased with class III drugs. However, the multivariate Cox proportional hazards survival model revealed that maintenance of sinus rhythm was influenced by several factors, such as presence of cardiomyopathy and prior medical treatment for AF, which seems reasonable because rhythm-control therapy is known to be difficult in patients with structural heart disease such as hypertrophic cardiomyopathy. Although these independent factors were not associated with the patients taking class III drugs, involvement of some unidentified underlying factors can not be denied because of the relatively small number of patients in this group of AAs.
Although amiodarone is considered the final choice for PAF patients in Japan, because of its serious side-effect, there is certain evidence that amiodarone prevents AF recurrence in patients with structural heart disease. 5, 6, 22, 23 Therefore, further analysis should be performed to confirm the effect of amiodarone vs bepridil in Japanese patients with PAF.
Another insight gained from this subanalysis regards aprindine, a class Ib drug that was eliminated from the list of first-choice drugs for lone AF in the new "Guidelines of Pharmacotherapy of Atrial Fibrillation (JCS 2008)". However, our analysis shows that oral aprindine has similar efficacy to class Ia and Ic drugs, which could not be presented before publication of the guideline. The elimination of the drug from the new guideline was primarily based on a discussion among members about the frequency of aprindine usage in the J-RHYTHM study and a previous randomized trial demonstrating no beneficial effect of the drug over digoxin. 24 
Study Limitations
We initially tried to compare each AA, but because the number of patients in each AA group was limited, we classified the drugs by the Vaughan Williams classification, which is not based on their activity against cardiac ion channels or arrhythmogenic mechanisms. The Sicilian Gambit classification 25 would be more suitable for addressing the issue, but is difficult for actual analysis. Furthermore, the choice of the AAs used in the J-RHYTHM study was not blinded to physicians and patients, which could lead to biases in the occurrence of endpoints and AF recurrence. Although we attempted to adjust for known clinical varieties, unidentified confounders could have affected the outcome.
Second, although it is a standard method of assessing maintenance of sinus rhythm, [5] [6] [7] [8] [16] [17] [18] [19] 22, 23 snapshot ECGs may underestimate the recurrence of asymptomatic AF.
Conclusion
Our subanalysis of the J-RHYTHM study demonstrated that the incidence of a primary endpoint did not differ between each group of drugs classified by the Vaughan Williams classification. However, the recurrence of AF was high in patients given class III drugs, which may have resulted from some unknown confounding factors. Tables 1,2. 
